Third Potential Carcinogen Found in Blood-Pressure Drugs

Doctor measuring patient's blood pressure

Multiple Drug Companies Recall Blood Pressure Medications Over Cancer Risks East News Altopress

That's after trace amounts of a potential carcinogen were found to be in the medicine.

Questions about the recalled blood pressure medication can be directed to Camber Pharmaceuticals' Med Line at 1-866-495-1995, Monday through Friday from 9 a.m.to 5 p.m. ET.

The U.S. Food and Drug Administration said Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets due to detection of trace amounts of an unexpected impurity.

Problems with potential cancer-causing agents in blood-pressure medications first cropped up in July, when an ARB called valsartan was recalled by Chinese drugmaker Zhejiang Huahai Pharmaceutical Co. Ltd. The company said it hadn't received any reports of patients being harmed related to the recall.

The U.S. Food and Drug Administration announced another recall of blood pressure medication Friday because a potentially carcinogenic impurity was found in it.

But patients should speak with their doctor to discuss the recall before they stop taking the drug. The affected Losartan tablets have expiration dates that range from September 2019 to June 2020.

Justin Trudeau's Troubles Deepen as Second Canadian Minister Resigns
He said it raises "serious questions" about the alleged interference of Trudeau's government and its commitment to reconciliation. After some reflection, she said, it became clear it would be "untenable" for her to continue to serve as a cabinet minister.

Presently, Illinois-based compliance company Stericycle is working with Camber to notify distributors and customers of the recall.

In a statement, FDA Commissioner Scott Gottlieb explained that the agency has been carrying out a series of investigations for several months after various companies began announcing their voluntary recalls.

Previous recalls of Losartan and other angiotensin II receptor blockers, ARB medicines, such as Valsartan and Irbesertan have included two other possible carcinogens, such as N-nitrosodimethylamine or NDMA, and N-nitrosodiethylamine or NDEA. It is the second losartan recall in a week; Macleods Pharmaceuticals Limited recalled a single lot on February 22. Hetero Labs Limited produced the active ingredient.

The FDA said in a statement it was investigating the formation of these impurities, which were reported to be made by previously unknown to drug developers.

You can also find more information about the recall at this link.

Latest News